Stock 603739 QINGDAO VLAND BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Qingdao Vland Biotech INC. Share Price

Equities

603739

CNE100003GX8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
11.46 CNY +9.98% Intraday chart for Qingdao Vland Biotech INC. +18.14% -24.70%
25/04 Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
25/04 Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 1.44B 199M 16.57B Sales 2025 * 1.63B 224M 18.72B Capitalization 2.9B 400M 33.37B
Net income 2024 * 138M 19.05M 1.59B Net income 2025 * 160M 22.08M 1.84B EV / Sales 2024 * 2.01 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.78 x
P/E ratio 2024 *
21 x
P/E ratio 2025 *
18.2 x
Employees 1,590
Yield 2024 *
1.66%
Yield 2025 *
2.01%
Free-Float 32.37%
More Fundamentals * Assessed data

Chart Qingdao Vland Biotech INC.

Dynamic Chart

Latest news about Qingdao Vland Biotech INC.

Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Qingdao Vland Biotech Forms Chinese JV With Germany’s Evonik MT
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Qingdao Vland Biotech INC. completed the acquisition of 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders. CI
Qingdao Vland Biotech Acquires 51% of Runbot Biotechnology for 91.8 Million Yuan MT
Qingdao Vland Biotech INC. signed a share transfer agreement to acquire a 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders for CNY 91.8 million. CI
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Qingdao Vland Biotech's Joint Venture to Invest Up to 400 Million Yuan for Probiotic Food Plant MT
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news

Quotes and Performance

1 day+9.98%
1 week+18.14%
1 month-4.58%
3 months-5.60%
6 months-15.67%
Current year-24.70%
More quotes

Highs and lows

1 week
9.50
Extreme 9.5
11.46
1 month
9.03
Extreme 9.03
12.27
Current year
7.70
Extreme 7.7
15.17
1 year
7.70
Extreme 7.7
18.26
3 years
7.70
Extreme 7.7
20.52
5 years
7.70
Extreme 7.7
30.54
10 years
7.70
Extreme 7.7
30.54
More quotes

Managers and Directors - Qingdao Vland Biotech INC.

Managers TitleAgeSince
Gang Chen CEO
 Chief Executive Officer 49 12/14/12
Pi Yuan Qiao DFI
 Director of Finance/CFO 47 20/17/20
Bing Liang Huang BRD
 Director/Board Member 69 20/17/20
Members of the board TitleAgeSince
Bing Liang Huang BRD
 Director/Board Member 69 20/17/20
De Qiang Jia BRD
 Director/Board Member 54 20/11/20
Pi Yuan Qiao DFI
 Director of Finance/CFO 47 20/17/20
More insiders

Quotes

Date Price Change Volume
26/24/26 11.46 +9.98% 8,056,540
25/24/25 10.42 +2.46% 2,380,140
24/24/24 10.17 +0.39% 2,219,400
23/24/23 10.13 +3.16% 2,614,360
22/24/22 9.82 +1.24% 2,500,280

End-of-day quote Shanghai S.E., April 26, 2024

More quotes

Company Profile

Qingdao Vland Biotech Co., Ltd. is a China-based company which mainly develops, produces and sells enzyme preparations, micro-ecology and animal health products. The Company's main products are enzyme preparations, micro-ecology and animal health products, such as feed enzymes, industrial enzymes, food enzymes, plant micro-ecological preparations, veterinary chemicals and veterinary drugs. The Company's products are mainly used in the washing, textile, food, feed, paper, energy and pharmaceutical industries. The Company mainly distributes its products in China and overseas markets.
Sector
Biotechnology & Medical Research
Calendar
28/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Qingdao Vland Biotech INC.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.46
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
QINGDAO VLAND BIOTECH INC. Stock Qingdao Vland Biotech INC.
-24.70% 400M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 603739 Stock